1. Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial. (3rd October 2022) Authors: Ang, F; Rapattoni, W; Bajaj, H S; Mancini, G B J; Poirier, P; Sharma, A; Wong, N C; Slee, A; Levin, A; Mahaffey, K W Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗